Related Experiment Video
Updated: Aug 2, 2026
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Downregulation of CX3CR1 ameliorates experimental colitis: evidence for CX3CL1-CX3CR1-mediated immune cell
Felix Becker1,2, Christina Holthoff1, Christoph Anthoni1
1Department of General and Visceral Surgery, University Hospital Muenster, Waldeyerstraße 1, 48149, Muenster, Germany.
Insights
The CX3CL1-CX3CR1 pathway is crucial for immune cell recruitment in experimental colitis. Blocking CX3CR1 may offer a new therapeutic strategy for inflammatory bowel diseases (IBD).
Area of Science:
- Immunology
- Gastroenterology
- Molecular Biology
Background:
- Inflammatory bowel diseases (IBD) involve significant immune cell infiltration.
- The CX3CL1 chemokine ligand and its receptor CX3CR1 play roles in leukocyte adhesion and recruitment.
- Understanding this pathway is key to developing new IBD treatments.
Purpose of the Study:
- To investigate the role of CX3CL1-CX3CR1 signaling in immune cell recruitment during experimental murine colitis.
- To elucidate the mechanisms underlying leukocyte and platelet recruitment in colitis.
Main Methods:
- Experimental colitis induced using dextran sodium sulfate (DSS) and sepsis via lipopolysaccharide (LPS).
- Serum levels of CX3CR1 and CX3CL1 measured by ELISA.
- Intravital microscopy used to assess colonic leukocyte and platelet recruitment in wild-type and CX3CR1 knockout mice.
Main Results:
- CX3CR1 was upregulated in DSS colitis and LPS-induced sepsis models.
- Mice lacking CX3CR1 showed reduced disease severity and intestinal injury in DSS colitis.
- CX3CR1 deficiency led to decreased rolling of leukocytes and platelets in the colon.
Conclusions:
- CX3CL1-CX3CR1 signaling is critical for intestinal leukocyte recruitment in experimental colitis.
- CX3CR1 blockade emerges as a potential therapeutic approach for IBD treatment.
Purpose:
Inflammatory conditions like inflammatory bowel diseases (IBD) are characterized by increased immune cell infiltration. The chemokine ligand CX3CL1 and its receptor CX3CR1 have been shown to be involved in leukocyte adhesion, transendothelial recruitment, and chemotaxis. Therefore, the objective of this study was to describe CX3CL1-CX3CR1-mediated signaling in the induction of immune cell recruitment during experimental murine colitis.
Methods:
Acute colitis was induced by dextran sodium sulfate (DSS), and sepsis was induced by injection of lipopolysaccharide (LPS). Serum concentrations of CX3CR1 and CX3CL1 were measured by ELISA. Wild-type and CX3CR1-/- mice were challenged with DSS, and on day 6, intravital microscopy was performed to monitor colonic leukocyte and platelet recruitment. Intestinal inflammation was assessed by disease activity, histopathology, and neutrophil infiltration.
Results:
CX3CR1 was upregulated in DSS colitis and LPS-induced sepsis. CX3CR1-/- mice were protected from disease severity and intestinal injury in DSS colitis, and CX3CR1 deficiency resulted in reduced rolling of leukocytes and platelets.
Conclusions:
In the present study, we provide evidence for a crucial role of CX3CL1-CX3CR1 in experimental colitis, in particular for intestinal leukocyte recruitment during murine colitis. Our findings suggest that CX3CR1 blockade represents a potential therapeutic strategy for treatment of IBD.
